Supplemental Figure 2 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer

Read full text Summarise with VIRAT
Authors: Sarah K. Herzog, Jessica H. Stevens, Guowei gu, Sandra L. Grimm, Kloma T Cardoza, Autumn G.M. Hawkins, Hangqing Lin, Daniela Ramos, Amanda R. Beyer, David G. Edwards, Derek J. Dustin, Harry J. Yang
+7 more Nicole Liang, Ashfia Fatima Khan, Tasneem Bawa-Khalfe, Daniel James McGrail, Shiaw‐Yih Lin, Cristian Coarfa, Suzanne A.W. Fuqua
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ESR1m defective RSR signature shows prognostic association with disease specific survival (DSS) in the METABRIC ER+ breast cancer cohort Kaplan-Meier plot of high (top 50%) versus low (bottom 50%) of patients expressing the ESR1 mutant defective replication stress response signature in the METABRIC ER+ patient cohort. P-values were determined utilizing the log-rank test.

Fields of Study & Subjects

Breast Cancer Treatment Studies Estrogen and related hormone effects Advanced Breast Cancer Therapies

Publication details

Publication date
2 April 2026
Language
EN